VIB-RUG Department of Molecular Biomedical Research

Molecular ImmunoBiotechnology Unit

 

 

 

 

 

 

 

 

Therapeutic monoclonal antibodies used in clinical practice anno 2004.

 

Generic name

Trade name

Target

Sponsor Co.

 

Type

1

Muromonab

Orthoclone OKT3

CD3

Ortho Biotech

1986

Murine

2

Abciximab

ReoPro

Platelet GP IIb/IIIa

Centocor

1994

Murine

3

Rituximab

Rituxan

CD20

Genentech

1997

Chimeric

4

Daclizumab

Zenapax

IL2Ra (CD25)

Hoff.-LaRoche

1997

Humanized

5

Basiliximab

Simulect

IL2R

Novartis

1998

Chimeric

6

Palivizumab

Synagis

RSV

MedImmune

1998

Humanized

7

Infliximab

Remicade

TNFa

Centocor

1998

Chimeric

8

Trastuzumab

Herceptin

Her2/neu/ErbB2

Genentech

1998

Humanized

9

Gemtuzumab

Mylotarg

CD33

Wyeth-Ayerst

2000

Humanized

10

Alemtuzumab

Campath-1H

CD52

Millenium/ILEX

2001

Humanized

11

Endrecolomab

Panorex

17A-1

Glaxo-Wellcome

 

Humanized  

12 Ibritumomab tiuxetan Zevalin CD20 Biogen IDEC 2002 Chimeric
13 Adalimumab Humira TNFa Abbot 2002 Human
14 Omalizumab Xolair IgE Genentech/Novartis 2003 Humanized
15 Centuximab Erbitux EGFR/ErbB1/Her1 ImClone/BMS/Merck 2004 Humanized
16 Bevacisumab Avastin VEGF Genentech 2004 Humanized
17 Efalizumab Raptiva CD11a Genentech/Xoma   Humanized

(1)    Induces T-cell anergy to prevent graft rejection after transplantation

(2)    Binds Integrin: prevents clothing by preventing platelet aggregation (during surgery), angioplasty   

(3)    B-cell lymphoma (NHL) marker: trigger kills lymphoma cell: first line medication

(4)    Acute graft rejection after renal transplantation (also liver)

(5)    Acute graft rejection after renal transplantation (also liver)

(6)    RSV: prevents infection in premature children

(7)    Prevents inflammation (TH1) in rheumatoid arthritis (RA) and Crohn’s disease.

(8)    Carcinoma marker, kills tumor cells: breast cancer treatment

(9)    Relapsed acute myeloid leukemia, antibody-targeted chemotherapy (ATC)

(10) Allogeneic transplant, RA, lymphoma, leukemia, vasculitis, multiple sclerosis, malignant T-cell purging

(11) Colorectal cancer marker (not signaling)

(12) radioimmunotherapy treatment for non-Hodgkins lymphoma

(13) Rheumatoid arthritis

(14) Allergy

(15) Colon cancer

(16) anti angiogenesis in metastatic colon cancer

 

And more than 300 in clinical trails....

 

 

[Antibodies] [Immunotherapy] [BsAb] [Tribody]

 

Home

Contact

Research projects

Publications

After eight

Check out 

links to:

MABs on the market
Antibody Companies
Immune Therapy Companies
Custom protein expression and purification
Biotech in Flanders
Flanders Universities
Flanders Biotech Policy

                  

© 2002 Webmaster